GRI Bio Presents Preclinical Data Indicating Oral Administration Of GRI-0803 Inhibited Lupus Nephritis And Significantly Improved Overall Survival In Animal Models
Portfolio Pulse from Benzinga Newsdesk
GRI Bio has presented preclinical data indicating that oral administration of GRI-0803 inhibited lupus nephritis and significantly improved overall survival in animal models. The company expects to commence Phase 1a/b SLE study in 1H 2024 with topline results expected 2H 2024.
August 07, 2023 | 12:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
GRI Bio's preclinical data on GRI-0803 shows potential in treating lupus nephritis. The company is set to commence Phase 1a/b SLE study in 1H 2024.
The positive preclinical data for GRI-0803 indicates potential for the drug's success in treating lupus nephritis. This could lead to increased investor interest and potential stock price increase for GRI Bio in the short term, especially as the company moves towards Phase 1a/b SLE study in 1H 2024.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100